HOPKINTON, Mass. and TOKYO, Aug. 9, 2024
/PRNewswire/ -- Phosphorex, a drug delivery-focused contract
development and manufacturing organization ("CDMO") backed by
Boston-based private equity firm
Ampersand Capital Partners, announced today that NOF CORPORATION
has completed a strategic investment into the company.
"This partnership will help us advance our
growth plans and enhance the value we provide to our clients and
stakeholders," said Jarlath Keating,
CEO of Phosphorex.
This partnership marks a significant milestone in Phosphorex's
growth and development journey as NOF's investment will be used to
accelerate the establishment of Phosphorex's cGMP capability while
further strengthening the collaboration between the two companies.
The addition of NOF CORPORATION as a shareholder underscores its
confidence in Phosphorex's innovative approach to enabling
nanoparticle-based drug delivery on a global scale.
"We are excited to welcome NOF CORPORATION as a minority
shareholder," said Jarlath Keating,
CEO of Phosphorex. "Their support and expertise will be invaluable
as we continue our vision of enabling the development of novel
therapeutics to improve the lives of patients. This partnership
will help us advance our growth plans and enhance the value we
provide to our clients and stakeholders."
"This investment is expected to bring numerous benefits to
Phosphorex, including increased funding, additional strategic
support, and other advantages," said Yuji
Yamamoto, General Manager of Life Science division of NOF
CORPORATION. "The collaboration with NOF CORPORATION will further
enable Phosphorex's mission to become the leading CDMO for
nanoparticle-based drug delivery solutions and consolidate NOF's
position in the lipid nanoparticle (LNP)-based drug delivery market
via its COATSOMEĀ® SS Series of proprietary ionizable lipids."
About Phosphorex
Phosphorex is a leading provider of drug delivery technologies
and solutions. By harnessing the potential of microspheres and
nanoparticles for drug delivery, Phosphorex offers tailored
solutions and enabling technologies to optimize a drug's release
rate, targeting ability, bioavailability, and deliverability, with
the goal of achieving desired therapeutic effects while reducing
adverse clinical outcomes. Phosphorex supports pharmaceutical and
biotech companies through all phases of their development, from
proof of concept to clinical studies. Phosphorex's mission is to
help our partners solve complex problems and develop successful
drugs to help patients. Additional information about Phosphorex is
available at www.phosphorex.com or follow us
on LinkedIn.
About NOF CORPORATION
The NOF Group pursues multi-faceted business development in
five divisions of activities based on its own technologies. Since
2001, DDS Development Division is organized within NOF's family of
complementary business units, offering innovation to pharmaceutical
and biomedical products. In April
2023, the DDS Development Division was renamed the Life
Science Division and will continue to contribute to the
pharmaceutical and medical fields. NOF supplies high-purity
phospholipids, diacylglycerol PEGs and proprietary ionizable lipids
as materials for LNP. For additional information, visit
www.nof.co.jp/english/business/life and dds-drug.com or
follow us on LinkedIn.
About Ampersand Capital Partners
Founded in 1988, Ampersand Capital Partners is a middle market
private equity firm with $3 billion
of assets under management dedicated to growth-oriented investments
in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a
unique blend of private equity and operating experience to build
value and drive long-term performance alongside its portfolio
company management teams. Ampersand has helped build numerous
market-leading companies across each of the firm's core healthcare
sectors. For additional information, visit
www.ampersandcapital.com or follow us on LinkedIn.
Media Contact: Kim Yang,
kyang@phosphorex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phosphorex-welcomes-nof-corporation-as-shareholder-and-strategic-partner-302218802.html
SOURCE Phosphorex LLC